Match tier
Confirmed
Presence
Current · Arkansas
Last published
2025
Sources
OpenAlex · ORCID
Refreshed
2026-08-15
A
Adam R. Wolfe
Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.
Assistant Professor
Also affiliated: Abbott Northwestern Hospital (2020); University of North Carolina Health Care (2017); The University of Texas MD Anderson Cancer Center (2012–2018); Baylor College of Medicine (2016); University of Arkansas Medical Center (2024); The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (2018–2021); The Ohio State University Wexner Medical Center (2018–2021); Winthrop Rockefeller Foundation (2021–2024); ORCID (2021); The Ohio State University (2018–2021)
Faculty Researcher
15 h-index
81 pubs
1,074 cited
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Adam R. Wolfe's research investigates mechanisms of radioresistance in cancer, with a focus on pancreatic cancer. His work has identified the inhibitor of DNA binding 1 (ID1) as a novel marker for radioresistance in pancreatic cancer, utilizing genome-wide RNA sequencing for its discovery. Further studies explore the role of the RAS-RAF-miR-296-3p signaling axis in augmenting radioresistance by increasing Rad18 expression in pancreatic and thyroid cancers. Wolfe also examines strategies to enhance radiosensitivity, such as the inhibition of Cyclin-dependent kinase 1 (CDK1) in pancreatic cancer cells. His research has also extended to other cancer types, investigating predictors of treatment response in lung cancer and the correlation of BRAF mutations with local-regional control in melanoma patients treated with radiation therapy. Collaborations include work with Oscar Zuniga, Henrique Rodrigues, Lokesh Akana, and Saaimatul Huq at the University of Arkansas for Medical Sciences.
Metrics
- h-index: 15
- Publications: 81
- Citations: 1,074
Selected Publications
-
Abstract A033: Targeting SETD2 in Combination with Radiotherapy in Rectal Cancer (2025)
-
SETD2 Loss Predicts Response to Chemoradiotherapy in Rectal Cancer: Clinical Outcomes and Preclinical Validation in Orthotopic Models (2025)
-
Grid Spatially Fractionated Radiation Therapy for Bulky Tumors: A Large Single Institution Experience (2025)
-
Enhancing Rectal Cancer Radiosensitivity and Gut Protection through Methionine Restriction (2025)
-
Spatially Fractionated Radiotherapy GRID for Bulky Tumor: A Large Single Institution Experience (2024)
-
Abstract A011: Enhanced Radiosensitivity of Pancreatic Cancer Achieved through Inhibition of Cyclin-Dependent Kinase 1 (2024)
-
Enhanced radiosensitivity of pancreatic cancer achieved through inhibition of Cyclin-dependent kinase 1 (2024)
-
RAS-RAF-miR-296-3p signaling axis increases Rad18 expression to augment radioresistance in pancreatic and thyroid cancers (2024)
-
Nutrient scavenging-fueled growth in pancreatic cancer depends on caveolae-mediated endocytosis under nutrient-deprived conditions (2024)
-
Abstract A006: Targeting SETD2 in combination with radiotherapy in rectal cancer (2024)
-
Ras-Raf-Mir-296-3p Signaling Axis Increases Rad18 Expression to Augment Radioresistance in Pancreatic and Thyroid Cancers (2023)
-
Outcomes of Moderately Dose Escalated Hypofractionated Chemoradiation for Pancreatic Cancer (2023)
-
Targeting Tri-Methyl-Histone H3 (Lys27) in Rectal Cancer: A Novel Strategy to Enhance Radiosensitivity and Predict Response to Neoadjuvant Therapy (2023)
-
Diagnostic discovery (2023)
-
Diagnostic testing (2023)
Collaboration Network
Top Collaborators
Terence M. Williams
City Of Hope National Medical Center (US)
6 shared publications
- Nutrient scavenging-fueled growth in pancreatic cancer depends on caveolae-mediated endocytosis under nutrient-deprived conditions
- BRAF mutation correlates with worse local–regional control following radiation therapy in patients with stage III melanoma
- RAS-RAF-miR-296-3p signaling axis increases Rad18 expression to augment radioresistance in pancreatic and thyroid cancers
- Development of a MicroRNA Signature Predictive of Recurrence and Survival in Pancreatic Ductal Adenocarcinoma
- Ras-Raf-Mir-296-3p Signaling Axis Increases Rad18 Expression to Augment Radioresistance in Pancreatic and Thyroid Cancers
Showing 5 of 6 shared publications
Oscar Zuniga
University of Arkansas for Medical Sciences
6 shared publications
In database
- RAS-RAF-miR-296-3p signaling axis increases Rad18 expression to augment radioresistance in pancreatic and thyroid cancers
- Ras-Raf-Mir-296-3p Signaling Axis Increases Rad18 Expression to Augment Radioresistance in Pancreatic and Thyroid Cancers
- 205 Targeting Homologous Repair to Overcome Genotoxic Therapy Resistance in Pancreatic Cancer
- Abstract 2839: Methionine restriction radiosensitizes KRAS mutant rectal cancer
- Abstract A006: Targeting SETD2 in combination with radiotherapy in rectal cancer
Showing 5 of 6 shared publications
Henrique Rodrigues
University of Arkansas for Medical Sciences
6 shared publications
In database
- RAS-RAF-miR-296-3p signaling axis increases Rad18 expression to augment radioresistance in pancreatic and thyroid cancers
- Abstract 2839: Methionine restriction radiosensitizes KRAS mutant rectal cancer
- Abstract A006: Targeting SETD2 in combination with radiotherapy in rectal cancer
- Abstract A011: Enhanced Radiosensitivity of Pancreatic Cancer Achieved through Inhibition of Cyclin-Dependent Kinase 1
- Enhancing Rectal Cancer Radiosensitivity and Gut Protection through Methionine Restriction
Showing 5 of 6 shared publications
Lokesh Akana
University of Arkansas for Medical Sciences
6 shared publications
In database
- Targeting Tri-Methyl-Histone H3 (Lys27) in Rectal Cancer: A Novel Strategy to Enhance Radiosensitivity and Predict Response to Neoadjuvant Therapy
- Abstract A006: Targeting SETD2 in combination with radiotherapy in rectal cancer
- Abstract A011: Enhanced Radiosensitivity of Pancreatic Cancer Achieved through Inhibition of Cyclin-Dependent Kinase 1
- Enhancing Rectal Cancer Radiosensitivity and Gut Protection through Methionine Restriction
- SETD2 Loss Predicts Response to Chemoradiotherapy in Rectal Cancer: Clinical Outcomes and Preclinical Validation in Orthotopic Models
Showing 5 of 6 shared publications
Saaimatul Huq
University of Arkansas for Medical Sciences
3 shared publications
In database
- Abstract A011: Enhanced Radiosensitivity of Pancreatic Cancer Achieved through Inhibition of Cyclin-Dependent Kinase 1
- Enhancing Rectal Cancer Radiosensitivity and Gut Protection through Methionine Restriction
- Abstract A033: Targeting SETD2 in Combination with Radiotherapy in Rectal Cancer
Eric D. Miller
The Ohio State University (US)
2 shared publications
- BRAF mutation correlates with worse local–regional control following radiation therapy in patients with stage III melanoma
- Outcomes of Moderately Dose Escalated Hypofractionated Chemoradiation for Pancreatic Cancer
Amy Webb
The Ohio State University (US)
2 shared publications
- Nutrient scavenging-fueled growth in pancreatic cancer depends on caveolae-mediated endocytosis under nutrient-deprived conditions
- Development of a MicroRNA Signature Predictive of Recurrence and Survival in Pancreatic Ductal Adenocarcinoma
Ryan Robb
University of North Carolina at Chapel Hill (US)
2 shared publications
- Nutrient scavenging-fueled growth in pancreatic cancer depends on caveolae-mediated endocytosis under nutrient-deprived conditions
- Development of a MicroRNA Signature Predictive of Recurrence and Survival in Pancreatic Ductal Adenocarcinoma
Óscar Zúñiga
University of Arkansas for Medical Sciences
2 shared publications
In database
- Discovery of the inhibitor of DNA binding 1 as a novel marker for radioresistance in pancreatic cancer using genome-wide RNA-seq
- Abstract A011: Enhanced Radiosensitivity of Pancreatic Cancer Achieved through Inhibition of Cyclin-Dependent Kinase 1
Sarita Garg
University of Arkansas for Medical Sciences
2 shared publications
In database
- Abstract 2839: Methionine restriction radiosensitizes KRAS mutant rectal cancer
- Enhancing Rectal Cancer Radiosensitivity and Gut Protection through Methionine Restriction
Stetson Van Matre
University of Arkansas for Medical Sciences
2 shared publications
In database
- Abstract 2839: Methionine restriction radiosensitizes KRAS mutant rectal cancer
- Abstract A011: Enhanced Radiosensitivity of Pancreatic Cancer Achieved through Inhibition of Cyclin-Dependent Kinase 1
Nükhet Aykin‐Burns
University of Arkansas for Medical Sciences
2 shared publications
In database
- Abstract 2839: Methionine restriction radiosensitizes KRAS mutant rectal cancer
- Enhancing Rectal Cancer Radiosensitivity and Gut Protection through Methionine Restriction
Isabelle R. Miousse
University of Arkansas for Medical Sciences
2 shared publications
In database
- Abstract 2839: Methionine restriction radiosensitizes KRAS mutant rectal cancer
- Enhancing Rectal Cancer Radiosensitivity and Gut Protection through Methionine Restriction
Rahul N. Prasad
The Ohio State University Wexner Medical Center (US)
2 shared publications
- Diagnostic discovery
- Diagnostic testing
Haley K. Perlow
The Ohio State University Wexner Medical Center (US)
2 shared publications
- Diagnostic discovery
- Diagnostic testing
Similar Researchers
Based on overlapping research topics
Robin Eluvathingal
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research
Radiation Therapy and Dosimetry
J.T. Pilkington
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Genomics and Phylogenetic Studies
Metabolism and Genetic Disorders
Μ. D. Willard
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research
Metabolism and Genetic Disorders
Arafat Shabbir
University of Arkansas at Pine Bluff
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research
Genomics and Phylogenetic Studies
Susan Harley
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research
Genomics and Phylogenetic Studies
Jacob L Edmondson
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research
Genomics and Phylogenetic Studies